Data gathered: October 7
AI Stock Analysis - Vaxart (VXRT)
Analysis generated August 28, 2025. Powered by Chat GPT.
Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant vaccines based on its proprietary VAAST platform. It aims to revolutionize the approach to immunizations by providing oral vaccines that drive both systemic and mucosal immune responses, potentially offering a higher degree of protection and convenience compared to traditional injectable vaccines.
Stock Alerts - Vaxart (VXRT)
 |
Vaxart | September 24 Price is down by -6% in the last 24h. |
|
Vaxart | September 23 Price is down by -8.4% in the last 24h. |
|
Vaxart | September 16 Price is up by 6.4% in the last 24h. |
|
Vaxart | September 15 Price is down by -6.9% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Vaxart
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 99 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 525 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 75,004 | Sign up | Sign up | Sign up |
| Twitter Mentions | 28 | Sign up | Sign up | Sign up |
| X Mentions | 13 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Vaxart
Vaxart, Inc., a clinical-stage biotechnology company, is dedicated to the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company is headquartered in South San Francisco, California.
| Price | $0.35 |
| Target Price | Sign up |
| Volume | 696,320 |
| Market Cap | $83M |
| Year Range | $0.3 - $0.77 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Vaxart (NASDAQ:VXRT) Shares Pass Below Two Hundred Day Moving Average – Here’s WhySeptember 30 - ETF Daily News |
 |
Vaxart wthdraws reverse stock split proposalSeptember 19 - Thefly.com |
Vaxart Announces Withdrawal of Reverse Stock Split ProposalSeptember 19 - GlobeNewswire |
|
|
Vaxart shareholders reiterate intent to vote against reverse stock splitSeptember 18 - Thefly.com |
Vaxart Appoints W. Mark Watson as Lead Independent DirectorSeptember 17 - GlobeNewswire |
|
 |
Vaxart, Inc. (VXRT) Presents at H.C. Wainwright 27th Annual Global Investment Conference - SlideshowSeptember 11 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 40M | 0 | 0 | -15M | 0 | -0.070 |
| Q1 '25 | 21M | 0 | 21M | -16M | -12M | -0.070 |
| Q4 '24 | 15M | 1.1M | 15M | -12M | -8.6M | -0.050 |
| Q3 '24 | 4.9M | 0 | 4.9M | -14M | -11M | -0.060 |
| Q2 '24 | 6.4M | 17M | 6.4M | -16M | -14M | -0.090 |
Insider Transactions View All
| Finney Kevin filed to buy 204,771 shares at $0.4. August 19 '25 |
| Finney Kevin filed to buy 104,771 shares at $0.4. August 19 '25 |
| Watson W. Mark filed to buy 104,125 shares at $0.4. July 31 '25 |
| Finney Kevin filed to buy 78,897 shares at $0.4. August 19 '25 |
| Finney Kevin filed to buy 38,897 shares at $0.4. August 19 '25 |
Similar companies
Read more about Vaxart (VXRT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, x mentions, news mentions & customer reviews.
What is the Market Cap of Vaxart?
The Market Cap of Vaxart is $83M.
What is the current stock price of Vaxart?
Currently, the price of one share of Vaxart stock is $0.35.
How can I analyze the VXRT stock price chart for investment decisions?
The VXRT stock price chart above provides a comprehensive visual representation of Vaxart's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Vaxart shares. Our platform offers an up-to-date VXRT stock price chart, along with technical data analysis and alternative data insights.
Does VXRT offer dividends to its shareholders?
As of our latest update, Vaxart (VXRT) does not offer dividends to its shareholders. Investors interested in Vaxart should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Vaxart?
Some of the similar stocks of Vaxart are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.
